Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this observational study publication.

Concerns about the cardiovascular safety of recombinant human growth hormone (rhGH) treatment in childhood have recently been raised; however, long-term studies are limited.

Treatment with rhGH during childhood and adolescence (aged 0-18 years).

Who Took Part

The age groups tagged for this paper are infants, young children, children, teenagers, young adults and adults, both men and women.

This nationwide population-based cohort study included patients treated with rhGH during childhood from January 1, 1985, to December 31, 2010, in Sweden, with follow-up through December 31, 2014.

Included patients were treated with rhGH owing to isolated growth hormone deficiency (GHD), small for gestational age (SGA), and idiopathic short stature (ISS).

How the Study Was Run

For each patient, 15 age-, sex-, and region-based matched control individuals were randomly selected from the general population as a comparison group.

Data on cardiovascular outcomes and covariates including gestational age, birth weight, birth length, socioeconomic status, and height were obtained through linkage with several health care and population-based registers.

Data were analyzed from January 1, 1985, to December 31, 2014.

What Was Measured

The subject headings attached to it are Cardiovascular Diseases, Case-Control Studies, Human Growth Hormone, Incidence, Kaplan-Meier Estimate, Patient Acuity and Registries.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (JAMA pediatrics), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.